Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3526 |
| PDBID: | 7CZD |
| Chains: | A_B |
| Organism: | Lama glama, Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 1.64 |
| Reference: | 10.1136/jitc-2020-002131 |
| Antibody | |
| Antibody: | PM1003 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Programmed cell death 1 ligand 1(PD-L1) |
| Antigen mutation: | No |
| Durg Target: | Q9NZQ7 |
Sequence information
Antibody
Chain: A
Mutation: NULL
| >7CZD_A|Chain A, C|anti-PD-L1 VHH|Lama glama (9844) EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSDSSSTYYRDSVKGRFTISRDNAKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGTQVTVSSD |
Antigen
Chain: B
Mutation: NULL
| >7CZD_B|Chain B, D|Programmed cell death 1 ligand 1|Homo sapiens (9606) MFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPY |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: SER31 TYR32 TRP33 TYR35 LEU37 GLY42 LYS43 GLY44 LEU45 GLU46 TRP47 SER50 SER53 TYR59 ARG61 LYS98 ASP99 PRO100 GLY101 GLY102 TYR103 B: MET18 PHE19 ALA51 ALA52 ILE54 TYR56 GLU58 ASN63 GLN66 VAL68 HIS69 ASP73 LYS75 VAL76 ARG113 MET115 ILE116 SER117 GLY119 GLY120 ALA121 ASP122 TYR123 ARG125 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
